Immunome, Inc. (NASDAQ:IMNM) Receives $31.50 Consensus Target Price from Analysts

Immunome, Inc. (NASDAQ:IMNM) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $32.67.

Several equities research analysts have commented on the stock. Wedbush boosted their target price on shares of Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. SVB Leerink started coverage on shares of Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Finally, Guggenheim started coverage on shares of Immunome in a research report on Monday, April 15th. They issued a “buy” rating and a $35.00 price objective on the stock.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $15.48 on Monday. The firm has a market capitalization of $924.06 million, a P/E ratio of -2.87 and a beta of 1.66. Immunome has a one year low of $4.44 and a one year high of $30.96. The company’s fifty day moving average is $22.88 and its two-hundred day moving average is $14.97.

Immunome (NASDAQ:IMNM) last issued its earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The company had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $3.40 million. Immunome had a negative return on equity of 69.74% and a negative net margin of 761.92%. On average, sell-side analysts forecast that Immunome will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. TD Asset Management Inc acquired a new position in shares of Immunome during the 3rd quarter valued at about $1,063,000. Acadian Asset Management LLC acquired a new stake in Immunome during the 3rd quarter worth approximately $414,000. Emfo LLC acquired a new stake in Immunome during the 4th quarter worth approximately $633,000. Dorsey Wright & Associates acquired a new stake in Immunome during the 3rd quarter worth approximately $26,000. Finally, Renaissance Technologies LLC acquired a new stake in Immunome during the 1st quarter worth approximately $80,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.